Clinical Trials Browser

Oligometastatic Prostate Cancer (OMPC)

Prostatic Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Carcinoma, Transitional Cell

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Carcinoma, Renal Cell

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Urothelial Cancer

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Renal Cell, Lymphatic Metastasis

Metastatic Castration-sensitive Prostate Cancer

Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Neoplasms

Carcinoma, Carcinoma, Renal Cell

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Prostate Cancer Metastatic

Prostatic Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Renal Cell

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Clinical Trials

PSMA-DC

OPTION-DDR

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

MK-5684-004

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Savolitinib vs. Sunitinib in MET-driven PRCC.

POTOMAC

VOLGA

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

ASCENDE-SBRT

TRIPLE-SWITCH

KLK2-PASenger

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

SPARTAN

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TITAN

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

THOR

MAGNITUDE

PROTEUS

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

AMPLITUDE

PRIMORDIUM

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

SunRISe-2

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

SunRISe-3

SunRISe-5

MoonRISe-1

MK-2400-001

KLK2-comPAS

LITESPARK-033

TroFuse-031

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

CLARIFY

AMPLIFY

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

OMAHA-003

Solar-Stage

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

STRIKE

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

GAIN-BCG